This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • B of A Securities analyst Joshua Dennerlein initiated coverage on MSCI Inc. MSCI with a Neutral rating and announced a price target of $585. MSCI shares closed at $549.33 on Wednesday. See how other analysts view this stock.
  • Mizuho initiated coverage on MannKind Corporation MNKD with an Outperform rating and announced a price target of $12. MannKind shares closed at $4.69 on Wednesday. See how other analysts view this stock.
  • Jefferies analyst Kelly Shi initiated coverage on Verastem, Inc. VSTM with a Buy rating and announced a price target of $15. Verastem shares closed at $5.28 on Wednesday. See how other analysts view this stock.
  • JP Morgan analyst Tami Zakaria initiated coverage on Westinghouse Air Brake Technologies Corporation WAB with a Neutral rating and announces Price Target of $175. Westinghouse Air Brake shares closed at $175.82 on Wednesday. See how other analysts view this stock.
  • Stifel analyst Annabel Samimy initiated coverage on Ligand Pharmaceuticals Incorporated LGND with a Buy rating and announced a price target of $143. Ligand Pharmaceuticals shares closed at $103.85 on Wednesday.  See how other analysts view this stock.

Considering buying LGND stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

LGND Logo
LGNDLigand Pharmaceuticals Inc
$104.272.94%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
87.71
Growth
-
Quality
-
Value
8.76
Price Trend
Short
Medium
Long
Got Questions? Ask
Which analysts see potential in MSCI?
How might MannKind Corporation benefit from its rating?
What factors could drive Verastem towards its price target?
Which investors are likely to favor Westinghouse?
How could Ligand Pharmaceuticals leverage its bullish outlook?
What trends may affect MSCI's market performance?
Could MannKind's new rating attract institutional investors?
What risks could impact Verastem's future growth?
How will WAB's neutral rating influence its stock price?
Are there hidden gems among pharmaceutical stocks like LGND?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: